OCULAR THERAPEUTIX INC's ticker is OCUL and the CUSIP is 67576A100. A total of 126 filers reported holding OCULAR THERAPEUTIX INC in Q1 2023. The put-call ratio across all filers is 0.49 and the average weighting 0.9%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $211,021 | -3.2% | 67,204 | +59.1% | 0.00% | – |
| Q2 2023 | $217,907 | -2.8% | 42,230 | -0.7% | 0.00% | – |
| Q1 2023 | $224,070 | -29.2% | 42,518 | -62.2% | 0.00% | -100.0% |
| Q4 2022 | $316,434 | +486.0% | 112,610 | +767.4% | 0.00% | – |
| Q3 2022 | $54,000 | -62.0% | 12,982 | -63.3% | 0.00% | – |
| Q2 2022 | $142,000 | +0.7% | 35,342 | +24.5% | 0.00% | – |
| Q1 2022 | $141,000 | -6.6% | 28,395 | +30.7% | 0.00% | – |
| Q4 2021 | $151,000 | -76.7% | 21,720 | -66.4% | 0.00% | -100.0% |
| Q3 2021 | $647,000 | -22.2% | 64,682 | +10.2% | 0.00% | 0.0% |
| Q2 2021 | $832,000 | -22.1% | 58,675 | -9.8% | 0.00% | -50.0% |
| Q1 2021 | $1,068,000 | +5.7% | 65,077 | +33.4% | 0.00% | 0.0% |
| Q4 2020 | $1,010,000 | +134.3% | 48,786 | -13.8% | 0.00% | +100.0% |
| Q3 2020 | $431,000 | -29.3% | 56,615 | -22.7% | 0.00% | 0.0% |
| Q2 2020 | $610,000 | +365.6% | 73,210 | +244.4% | 0.00% | – |
| Q3 2017 | $131,000 | – | 21,256 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SUMMER ROAD LLC | 6,122,089 | $32,263 | 100.00% |
| Opaleye Management Inc. | 6,105,900 | $32,178,093 | 9.64% |
| DELTEC ASSET MANAGEMENT LLC | 1,913,612 | $10,084,735 | 2.49% |
| Knoll Capital Management, LLC | 200,000 | $1,504,000 | 2.32% |
| Endurant Capital Management LP | 512,744 | $2,702,161 | 1.39% |
| Knoll Capital Management, LLC | 95,800 | $504,866 | 0.78% |
| Covestor Ltd | 60,008 | $316 | 0.28% |
| Ikarian Capital, LLC | 200,000 | $1,054,000 | 0.24% |
| EAM Investors, LLC | 224,211 | $1,181,592 | 0.23% |
| Nebula Research & Development LLC | 22,474 | $118,438 | 0.21% |